SYRS
Price:
$1.515
Market Cap:
$40.49M
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced sol...[Read more]
Industry
Biotechnology
IPO Date
2016-06-30
Stock Exchange
NASDAQ
Ticker
SYRS
According to Syros Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.35. This represents a change of -91.72% compared to the average of -4.23 of the last 4 quarters.
The mean historical PE Ratio of Syros Pharmaceuticals, Inc. over the last ten years is -2.96. The current -0.35 PE Ratio has changed 1.08% with respect to the historical average. Over the past ten years (40 quarters), SYRS's PE Ratio was at its highest in in the December 2022 quarter at 0.90. The PE Ratio was at its lowest in in the March 2015 quarter at -17.83.
Average
-2.96
Median
-3.08
Minimum
-5.82
Maximum
-0.92
Discovering the peaks and valleys of Syros Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 114.60%
Maximum Annual PE Ratio = -0.92
Minimum Annual Increase = -61.29%
Minimum Annual PE Ratio = -5.82
Year | PE Ratio | Change |
---|---|---|
2023 | -1.34 | 45.76% |
2022 | -0.92 | -59.18% |
2021 | -2.25 | -61.29% |
2020 | -5.82 | 58.01% |
2019 | -3.68 | 26.15% |
2018 | -2.92 | -36.19% |
2017 | -4.58 | 41.54% |
2016 | -3.23 | 114.60% |
2015 | -1.51 | -54.96% |
2014 | -3.35 | 55.68% |
The current PE Ratio of Syros Pharmaceuticals, Inc. (SYRS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.50
5-year avg
-2.80
10-year avg
-2.96
Syros Pharmaceuticals, Inc.’s PE Ratio is greater than Surrozen, Inc. (-0.55), greater than Bolt Biotherapeutics, Inc. (-0.37), greater than Larimar Therapeutics, Inc. (-8.80), greater than Keros Therapeutics, Inc. (-11.28), greater than Kezar Life Sciences, Inc. (-0.41), greater than IDEAYA Biosciences, Inc. (-18.36), greater than Syndax Pharmaceuticals, Inc. (-6.17), greater than Xencor, Inc. (-5.63), greater than REGENXBIO Inc. (-2.41), greater than Crinetics Pharmaceuticals, Inc. (-15.40), greater than Black Diamond Therapeutics, Inc. (-3.70), greater than Stoke Therapeutics, Inc. (-7.92), less than Homology Medicines, Inc. (-0.01), greater than Harpoon Therapeutics, Inc. (-2.94), greater than Passage Bio, Inc. (-0.57), less than Pasithea Therapeutics Corp. (-0.27), greater than Kronos Bio, Inc. (-0.58), greater than Quoin Pharmaceuticals, Ltd. (-0.47), greater than RenovoRx, Inc. (-3.02), less than Spero Therapeutics, Inc. (4.06), greater than Coherus BioSciences, Inc. (-4.85), greater than Gracell Biotechnologies Inc. (-12.26), greater than Neoleukin Therapeutics, Inc. (-0.98),
Company | PE Ratio | Market cap |
---|---|---|
-0.55 | $29.60M | |
-0.37 | $24.78M | |
-8.80 | $513.64M | |
-11.28 | $1.97B | |
-0.41 | $40.82M | |
-18.36 | $3.06B | |
-6.17 | $1.63B | |
-5.63 | $1.00B | |
-2.41 | $567.38M | |
-15.40 | $4.03B | |
-3.70 | $305.13M | |
-7.92 | $773.92M | |
-0.01 | $3.02M | |
-2.94 | $865.08M | |
-0.57 | $43.48M | |
-0.27 | $4.37M | |
-0.58 | $59.36M | |
-0.47 | $3.06M | |
-3.02 | $24.47M | |
4.06 | $71.07M | |
-4.85 | $142.86M | |
-12.26 | $989.87M | |
-0.98 | $8.20M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Syros Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Syros Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Syros Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Syros Pharmaceuticals, Inc. (SYRS)?
What is the highest PE Ratio for Syros Pharmaceuticals, Inc. (SYRS)?
What is the 3-year average PE Ratio for Syros Pharmaceuticals, Inc. (SYRS)?
What is the 5-year average PE Ratio for Syros Pharmaceuticals, Inc. (SYRS)?
How does the current PE Ratio for Syros Pharmaceuticals, Inc. (SYRS) compare to its historical average?